{"doi":"10.2217/fon.15.76","title":"Trabectedin clinical cases: use according to indication in diverse clinical scenarios","abstract":null,"journal":"Future Oncology","year":2015,"id":595571,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1500125,"name":"Javier Martín-Broto","orcid":null,"position":1,"is_corresponding":false},{"id":1525137,"name":"Markus Schuler","orcid":null,"position":2,"is_corresponding":false},{"id":1525138,"name":"Peter Reichardt","orcid":null,"position":3,"is_corresponding":false},{"id":459668,"name":"Giovanni Grignani","orcid":"0000-0001-5515-569X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Trabectedin clinical cases: use according to indication in diverse clinical scenarios","abstract":"BACKGROUND: Key distinguishing characteristics of trabectedin in the treatment of advanced soft tissue sarcoma are its prolonged tumor control activity in multiple histological subtypes, positive outcomes in translocation-related sarcomas, maintenance of response, option to rechallenge after treatment interruption and lack of cumulative toxicity. Trabectedin is indicated for use in advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, or as front-line treatment in patients unsuited to receive these agents. METHODS: In this review, cases studies are presented in which trabectedin was used according to its indication but in diverse clinical settings. RESULTS: As second-line treatment of uterine leiomyosarcoma, trabectedin produced prolonged tumor control with good quality of life. In treatment of recurrent synovial sarcoma, the best objective response (partial response) and longest disease control (37 months) was achieved under treatment with trabectedin. As neoadjuvant treatment of undifferentiated pleomorphic sarcoma in a patient unsuited to receive doxorubicin-based chemotherapy, trabectedin induced a pathological response with 85% of necrosis. CONCLUSION: These cases illustrate the broad range of indications for trabectedin in advanced soft tissue sarcoma and highlight how its unique characteristics can be optimized to achieve maximum clinical benefit.","is_dataset_classified":null,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26043311","pmcid":null,"openalex_id":"https://openalex.org/W2179832015","authors":[],"funders":[{"funder_name":"Amgen, Bayer, GlaxoSmithKline, Novartis, Pfizer and PharmaMar","grant_id":"","title":null},{"funder_name":"PharmaMar","grant_id":"","title":null},{"funder_name":"Bayer, Novartis and PharmaMar","grant_id":"","title":null},{"funder_name":"Amgen, Bayer, GSK and PharmaMar in advisory board meetings","grant_id":"","title":null}],"total_grants":4,"fwci":1.4164,"citation_percentile":0.83120111,"influential_citations":0,"citation_trend":[{"year":2016,"count":3},{"year":2017,"count":1},{"year":2018,"count":2},{"year":2019,"count":1},{"year":2021,"count":2},{"year":2022,"count":1},{"year":2024,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon.15.76","host_type":"publisher"},{"url":"https://doi.org/10.2217/fon.15.76","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26043311","host_type":"repository"}],"fields_of_study":["Sarcoma Diagnosis and Treatment","Uterine Myomas and Treatments","Angiogenesis and VEGF in Cancer","Anthracyclines","Antineoplastic Agents, Alkylating","Antineoplastic Combined Chemotherapy Protocols","Combined Modality Therapy","Contraindications","Dacarbazine","Deoxycytidine","Dioxoles","Female","Femoral Neoplasms","Humans","Hysterectomy","Ifosfamide","Leiomyosarcoma","Lung Neoplasms","Male","Middle Aged","Neoadjuvant Therapy","Radionuclide Imaging","Remission Induction","Salvage Therapy","Sarcoma","Sarcoma, Synovial","Soft Tissue Neoplasms","Tetrahydroisoquinolines","Thigh","Tomography, X-Ray Computed","Trabectedin","Treatment Outcome","Uterine Neoplasms","Gemcitabine"],"mesh_terms":["Contraindications","Trabectedin","Gemcitabine","Antineoplastic Combined Chemotherapy Protocols","Combined Modality Therapy","Dacarbazine","Deoxycytidine","Dioxoles","Female","Femoral Neoplasms","Humans","Hysterectomy","Ifosfamide","Leiomyosarcoma","Lung Neoplasms","Male","Middle Aged","Radionuclide Imaging","Remission Induction","Sarcoma","Soft Tissue Neoplasms","Sarcoma, Synovial","Thigh","Tomography, X-Ray Computed","Uterine Neoplasms","Salvage Therapy","Treatment Outcome","Antineoplastic Agents, Alkylating","Anthracyclines","Neoadjuvant Therapy","Tetrahydroisoquinolines"],"keywords":["Trabectedin","Medicine","Soft tissue sarcoma","Sarcoma","Ifosfamide","Oncology","Doxorubicin","Leiomyosarcoma","Internal medicine","Chemotherapy","Surgery","Pathology","Neoadjuvant chemotherapy","Synovial Sarcoma","Uterine Leiomyosarcoma","Undifferentiated Pleomorphic Sarcoma","Dosing Guidelines","Clinical Case Studies","Trabectedin Rechallenge"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T17:38:38.674850Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}